Implantable Drug Eluting Devices Market Overview:

Drug-eluting medical devices are active implants that, in addition to their primary function of support, also have the ability to generate therapeutic benefits. Controlled release of active pharmaceutical ingredients (API) into the surrounding tissue is used to achieve this effect. Each of these drug-eluting devices also offers a solution to the problem of drug release. The majority of drug-eluting vascular stents contain water-insoluble antiproliferative drugs, which take a long time to diffuse from the device to the surrounding tissue. When it comes to cardiology, ophthalmology, birth control, opioid addiction, pain management, diabetes management, contraception, and cancer therapy, implanted drug eluting devices are indispensable. The customised medication delivery systems help to increase treatment efficacy (oncology and cardiology) and reduce side effects by limiting damage to healthy tissue. Active drug eluting devices and passive drug eluting devices are the two basic types of implanted drug eluting devices. Electromechanical and osmotic pressure gradient technologies are primarily used in active drug eluting devices. Over the projected period, the market for implantable drug eluting devices is expected to rise at a healthy pace. This expansion is linked to the increasing use of patient-controlled devices and the increased incidence of peripheral and coronary artery disorders. Furthermore, the global market for implantable drug eluting devices is expected to develop as the incidence of cardiovascular and chronic diseases continues to rise. According to the World Health Organization, cardiovascular disease is one of the main causes of death worldwide. A number of research and clinical studies are under underway to improve the performance of existing drug-eluting stents and devices. Thus, research in this area focuses on the evaluation and development of innovative and enhanced drug eluting devices that provide significant clinical benefits while also addressing long-term safety issues.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Implantable Drug Eluting Devices Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Implantable Drug Eluting Devices Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Implantable Drug Eluting Devices Market:
• Pfizer Inc.
• Medtronic Inc.
• Merck & Co., In
• Bayer AG
• SurModics Inc.
• AstraZeneca Plc.
• Boston Scientific Corporation
• Titan Pharmaceuticals, Inc.
• Abbott Laboratories
• Allergan, Inc.
• Bausch and Lomb, Inc.
• Alimera Sciences
• REVA Medical, Inc.
(Note: The list of the major players will be updated with the latest market scenario and trends)

Implantable Drug Eluting Devices Market Segmentation:
By Product
• Implantable Drug Infusion Pumps
• Intraocular Drug Eluting Devices
• Contraceptive Drug Eluting Devices
• Buprenorphine Implant
• Drug Eluting Stents
• Others
By Technology
• Active Drug Eluting Device
• Passive Drug Eluting Device
 o Biodegradable Implants
 o Non-Biodegradable Implants
By Application
• Diabetic Macular Edema
• Birth Control/Contraception
• Opioid Addiction
• Cardiovascular
• Ophthalmology
• Oncology
• Pain Management
By Implementation Type
• Intravaginal
• Intravascular
• Intraocular
• Intrathecal
• Subcutaneous
• Intrauterine
By End User
• Hospitals
• Ambulatory Surgical Centers
• Optical Care Centers
• Cardiac Surgery Centers
• Office Based Settings
• Others
By Region
North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Implantable Drug Eluting Devices Market By Product, By Technology, By Application, By Implementation Type, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com


Need Assistance


UK : +44 141 628 9353
US : +1 347 709 4931


Contact Sales

What you get

  • Excel Dataset

  • Infographics

  • PDF Report

  • Market Overview

  • PowerPoint Presentation

What's included

  • Consumer Perception and Procurement

  • Competitive Analysis

  • What’s Next

  • Market Data Forecast

  • Risks and Opportunity Assessment

  • Market Trends and Dynamics